Schrödinger, a NYC-based provider of molecular modeling, drug design, and materials science software, completed the latest round with a total raise of $110m.
Backers included new investors Invus, Pavilion Capital, Oculus co-founder Michael Antonov through his investment fund, Tubus Management, Laurion Capital Management, and others. Previous investors in the round included the Bill and Melinda Gates Foundation Trust, WuXi AppTec’s Corporate Venture Fund, Deerfield Management, Baron, Qiming Venture Partners, and GV (formerly Google Ventures).
The company intends to use the funds for:
– advancement of its wholly-owned drug discovery pipeline,
– expansion of its collaborations with biopharma companies worldwide
– ongoing research and development efforts to extend the reach of its platform.
Led by CEO Ramy Farid, Ph.D., Schrödinger provides a proprietary technology platform, which integrates novel physics-based molecular simulations and machine learning to enable exploration of vastly more chemical space than is possible through traditional drug discovery methods.
The company licenses its computational platform to pharmaceutical, biotechnology, chemical, and electronics companies to accelerate R&D in both drug discovery and materials design.
Schrödinger has built a pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded biotech companies, including Nimbus Therapeutics and Morphic Therapeutic.
Founded in 1990, the company has nearly 400 employees in its New York City headquarters and around the world.